Document is current
Any future updates will be listed below
-
Authors
Yu, Wenliang
Li, Chenyang
Meng, Yuning
Li, Qiang
Gao, Mengyue
Tang, Wei
Li, Yao
Tan, Ziyi
Zhou, Xiaoran
Liu, Zeyang
Xu, Yun
Hua, Zichun https://orcid.org/0000-0001-7962-0402
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82130106)
National Natural Science Foundation of China (32250016)
National Natural Science Foundation of China (82404501)
National Natural Science Foundation of China (82303774)
Natural Science Foundation of Jiangsu Province (BK20230164)
Natural Science Foundation of Jiangsu Province (BK20243001)
Natural Science Foundation of Jiangsu Province (BE2023695)
Changzhou Municipal Department of Science and Technology (CJ20235009)
Changzhou Municipal Department of Science and Technology (CE20246001)
- License Information
-
More Information
Article History
Received: 7 May 2025
Revised: 30 October 2025
Accepted: 2 November 2025
First Online: 21 November 2025
Declarations
:
: All animal experiments were approved by Affidavit of Approval of Animal Ethical and Welfare of Nanjing university (Checking number: IACUC-D2403138), and were carried out in compliance with all relevant ethical regulations.
: Not applicable.
: “A personalized methotrexate application strategy based on the polymorphism at rs1544105 in the non-coding region of the FPGS gene” is a patent application (The patent number is 202511665323.7), but has no potential relevant financial or non‑financial interests to disclose. The authors Wenliang Yu and Zichun Hua are employees of Jiangsu TargetPharma Laboratories, Inc.. The other authors have no conflicts of interest to declare.
